Ulcerative Colitis Plasma

Ulcerative Colitis Plasma for Immune-Mediated Inflammatory Disease Research

Ulcerative Colitis Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of ulcerative colitis (UC) and processed within one day of collection to preserve labile analytes such as cytokines, acute-phase proteins, lipid mediators, and metabolites. Ulcerative colitis is an immune-mediated inflammatory bowel disease in which dysregulated mucosal immunity and epithelial barrier failure drive continuous inflammation of the colonic mucosa. Plasma provides the soluble, circulating readout of that process and is the appropriate matrix for protein, metabolite, and drug-level measurement.

Ulcerative Colitis Biology and Why Plasma

• UC is an immune-mediated inflammatory disease of the colon, not an autoantibody-driven condition: pathology reflects barrier dysfunction, microbial exposure, and sustained innate and T-cell-mediated mucosal inflammation rather than a defined autoantigen target.
• Systemic spillover of mucosal inflammation raises circulating acute-phase reactants such as C-reactive protein and serum amyloid A, which are widely used to gauge disease activity alongside endoscopic assessment.
• Effector cytokine pathways validated by approved therapies – TNF, IL-12/IL-23, JAK-STAT signalling, and lymphocyte trafficking via alpha4beta7 integrin and S1P receptors – can be interrogated in plasma through soluble mediators, receptor ectodomains, and drug concentration measurement.
• Markers of barrier breach and microbial translocation, including lipopolysaccharide-binding protein, soluble CD14, and intestinal fatty acid-binding protein, are measurable in plasma and complement stool-based assessment.
• Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) are detected more frequently in UC than in Crohn’s disease and are useful as an associated serological marker for donor characterisation, not as a proven driver of disease.
• Plasma is acellular, so it is suited to immunoassay, proteomic, metabolomic, and pharmacokinetic work; paired cellular specimens are available separately for functional and phenotypic studies.

Donor Stratification Available

• Disease extent: proctitis, left-sided colitis, or extensive colitis/pancolitis
• Disease state at collection: active flare versus documented clinical remission
• Treatment exposure: biologic-naive, anti-TNF, anti-integrin, anti-IL-23, or JAK inhibitor treated
• Conventional therapy background: aminosalicylates, thiopurines, or corticosteroids
• Surgical history, including prior colectomy or pouch formation
• Presence of extraintestinal manifestations such as arthropathy, uveitis, or primary sclerosing cholangitis
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed ulcerative colitis donors
• Processed within one day of collection
• Choice of anticoagulant (EDTA, sodium citrate, or heparin) on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified ulcerative colitis diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Disease extent, activity, and treatment history where documented
• Additional ulcerative colitis-specific metadata available on request

Applications

• Biomarker discovery and validation for flare prediction and remission monitoring
• Multiplex cytokine and chemokine profiling of TNF, IL-6, IL-17, IL-22, and IL-23 pathway mediators
• Acute-phase protein quantification, including CRP and serum amyloid A
• Untargeted and targeted plasma proteomics and metabolomics, including bile acid and short-chain fatty acid metabolite panels
• Gut barrier and microbial translocation marker measurement
• Pharmacokinetic and drug-tolerant assay development for biologic and small-molecule IBD therapeutics
• Anti-drug antibody and immunogenicity assay development
• Diagnostic assay development, reference-range establishment, and platform bridging studies

Other Ulcerative Colitis Specimen Types

• Ulcerative Colitis Serum
• Ulcerative Colitis Whole Blood
• Ulcerative Colitis PBMC
• Ulcerative Colitis Leukopak
• Ulcerative Colitis Bulk Plasma
• Ulcerative Colitis CD19+ B Cells
• Ulcerative Colitis CD4+ T Cells

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Ulcerative colitis plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse donor availability across all conditions, visit our human plasma page.